Hematology
Feature
Can convalescent plasma treat COVID-19 patients?
How COVID-19 patients can receive convalescent plasma, who is eligible to donate, and early results of treatment.
News from the FDA/CDC
FDA okays emergency use of convalescent plasma for seriously ill COVID-19 patients
“It’s crucial that data be captured for every patient so that we really understand what safety and effectiveness looks like on as close to a real-...
From the Journals
Sickle cell patients with vitamin D deficiency prone to more ED visits, longer stays
Screening for vitamin D deficiency may show benefits, authors suggest.
Conference Coverage
After PCI, stopping antiplatelet therapy for surgery appears safe
NATIONAL HARBOR, MD. –
Conference Coverage
Fear drives activity changes in hemophilia patients
Conference Coverage
BCL11A-directed gene therapy advances in sickle cell disease
ORLANDO – A phase 2/3 study is planned to assess the gene therapy in a larger group of patients with sickle cell disease.
Conference Coverage
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...
News from the FDA/CDC
FDA approves treatment for sickle cell pain crises
Crizanlizumab-tmca (Adakveo) is approved for patients with sickle cell disease who are aged 16 years and older.
Conference Coverage
Thromboembolic events more likely among CIDP patients with CVAD
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
From the Journals
Global blood supply runs low
Worldwide, more than 60% of countries had an inadequate supply of blood to meet the demand for transfusion.
From the Journals
Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS
Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists.